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Key Points
• The KIT inhibitor dasa-







both younger and older
patients with or without
KITmut.
Acutemyeloid leukemia (AML)witheither t(8;21)(q22;q22)or inv(16)(p13q22)/t(16;16)(p13;q22)
is referred to as core binding factor (CBF) AML. Although categorized as favorable risk,
long-term survival for these patients is only ;50% to 60%. Mutated (mut) or overexpressed
KIT, a gene encoding a receptor tyrosine kinase, has been found almost exclusively in
CBF AML and may increase the risk of disease relapse. We tested the safety and clinical
activity of dasatinib, a multi-kinase inhibitor, in combination with chemotherapy.
Sixty-one adult patients with AML and CBF fusion transcripts (RUNX1/RUNX1T1 or
CBFB/MYH11) were enrolled on Cancer and Leukemia Group B (CALGB) 10801. Patients
received cytarabine/daunorubicin induction on days 1 to 7 and oral dasatinib 100 mg/d
on days 8 to 21. Upon achieving complete remission, patients received consolidation
with high-dose cytarabine followed by dasatinib 100 mg/d on days 6 to 26 for 4 courses,
followed by dasatinib 100 mg/d for 12 months. Fifteen (25%) patients were older
(aged $60 years); 67% were CBFB/MYH11–positive, and 19% harbored KITmut. There
were no unexpected or dose-limiting toxicities. Fifty-five (90%) patients achieved complete
remission. With a median follow-up of 45 months, only 16% have relapsed. The 3-year
disease-free survival and overall survival rates were 75% and 77% (79% and 85%
for younger patients [aged ,60 years], and 60% and 51% for older patients). Patients
with KITmut had comparable outcome to those with wild-type KIT (3-year rates:
disease-free survival, 67% vs 75%; overall survival, 73% vs 76%), thereby raising the
question of whether dasatinib may overcome the negative impact of these genetic lesions.
CALGB 10801 was registered at www.clinicaltrials.gov as #NCT01238211.
Introduction
In acute myeloid leukemia (AML), t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22)
[hereafter referred to as t(8;21) and inv(16), respectively] are predictive of a more favor-
able outcome compared with most other cytogenetic/molecular subtypes, especially in patients
receiving consolidation with high-dose cytarabine (HiDAC) after achieving complete remission
(CR).1-3 However, despite being categorized as a favorable cytogenetic risk group, 40% to 50%
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of these patients still relapse, underscoring the need for more
effective therapeutic approaches.4-7
At the molecular level, t(8;21) and inv(16) result in fusion genes
(ie, RUNX1-RUNX1T1 and CBFB-MYH11, respectively) that lead
to the disruption of the RUNX1 and CBFB genes encoding the
subunits of the core binding factor (CBF) complex, a hetero-
dimeric transcription factor involved in the regulation of myeloid
hematopoiesis.8 However, transgenic, knock-in, and transduction
RUNX1-RUNX1T1 and CBFB-MYH11 mouse models have shown
that the fusion genes alone are not sufficient to cause a leukemic
phenotype and that additional genetic lesions are necessary for the
development of overt leukemia.9-12
Recent molecular analyses have identified gene signatures and
recurrent gene mutations associated with CBF AML. Mutations in
the KIT gene have been found in;25% of CBF AML patients and
are among the most frequent recurrent mutations.13-17 KIT is
located at chromosome band 4q12 and encodes a predicted
110-kD transmembrane glycoprotein that is a member of the type III
receptor tyrosine kinase family. After ligand binding, the receptor
dimerizes, becomes phosphorylated, and activates downstream
signaling pathways involved in cell proliferation, differentiation,
and survival. Ligand-independent activation of KIT can be caused
by gain-of-function mutations.8,18 In several studies, but not all,
KIT mutations have been associated with an inferior outcome in
patients with CBF AML, especially in t(8;21) where KIT mutations
confer a higher risk of relapse.14-19 In addition, regardless of
mutation status, KIT is also highly expressed in CBF AML blasts,20
and in vitro and in vivo models support cooperation of activated
KIT and CBF fusion proteins to induce and sustain AML growth.21,22
Therefore, despite some uncertainties regarding the prognostic
role of KIT mutations and KIT overexpression, there is a mecha-
nistic rationale for incorporating KIT inhibitors into the treatment of
CBF AML.
We report here the results of a prospective clinical trial that tested
the feasibility of adding dasatinib, an oral multi-kinase inhibitor with
activity on KIT and SRC activated proteins,23 to combination therapy
with a previously optimized Cancer and Leukemia Group B (CALGB)
cytarabine-daunorubicin/HiDAC-based chemotherapy regimen in
patients with CBF AML. The study also assessed the safety and
the clinical activity of this approach. CALGB is now part of the
Alliance for Clinical Trials in Oncology (Alliance).
Methods
Patients
Patients with previously untreated AML according to the World
Health Organization classification24 were eligible for molecular
screening for the CBF fusion transcripts RUNX1/RUNX1T1 or
CBFB/MYH11 in a CALGB/Alliance Molecular Pathology central
laboratory. All screened patients signed consent forms in compliance
with the Declaration of Helsinki for the Institutional Board Review–
approved protocols for molecular screening on CALGB 20202
and for treatment on CALGB 10801 (#NCT01238211). Patient
characteristics are summarized in Table 1.
Molecular screening for CBF fusion transcripts
Patients were centrally screened for the RUNX1/RUNX1T1 or
CBFB/MYH11 fusion transcripts by reverse transcription polymerase
chain reaction (RT-PCR). Bone marrow aspirate samples (or blood
with at least 20% circulating blasts) were shipped to the Alliance
Leukemia Tissue Bank. Samples were subjected to Ficoll density
gradient to collect mononuclear cells, which were resuspended in
RPMI 1640 with 20% albumin and submitted to the Alliance Molecular
Pathology central laboratory. RNA extraction and RT-PCR assays
forRUNX1/RUNX1T1 orCBFB/MYH11were performed as previously
reported.25 The presence of a CBF fusion transcript was confirmed in
all RT-PCR–positive samples by using Sanger sequencing–based
assays.
Molecular characterization of KIT status
KITmutations and expression analyses were performed as previously
reported.14,18 The median value ofKIT expression levels measured by
using quantitative RT-PCR was employed as a cutoff to define higher
vs lower expressers.20
Treatment
Treatment is summarized in the Visual Abstract and Table 2.
Patients received induction chemotherapy with cytarabine 200 mg/m2
per day continuous IV infusion on days 1 to 7, daunorubicin 60 mg/m2
per day IV bolus on days 1 to 3, and dasatinib (Sprycel, Bristol-Myers
Squibb) 100mg/d orally on days 8 to 21. Patients with residual disease
(.5% blasts) in a day 21 marrow aspirate were re-induced with the
same doses of cytarabine on days 1 to 5, daunorubicin on days 1 to
3, and dasatinib on days 6 to 19 of re-induction treatment. Patients
who achieved CR after 1 or 2 cycles of induction therapy received
consolidation with HiDAC 3000 mg/m2 (if aged ,60 years) or
1000 mg/m2 (if older), given IV over 3 hours every 12 hours on days
1, 3, and 5, and dasatinib 100 mg/d on days 6 to 26 for 4 courses.
Patients in CR after consolidation received dasatinib 100 mg daily
for 12 months.
Definition of clinical end points and
statistical analysis
The primary end point was safety as assessed by 30-day survival
after starting induction therapy. This two-stage phase 2 design
provided 90% power to identify a true 30-day survival rate
of$85% vs the null hypothesis that it is at most 70%. At least 59
evaluable patients were required for this two-stage trial, with an
interim analysis after the first 20 evaluable patients. Overall, the
regimen would be declared not feasible due to toxicity if$14 patients
($24%) among the first 59 evaluable patients experienced early or
Table 1. Patient characteristics
Characteristic Patients (N 5 61)
Male sex, n (%) 31 (51)
Age, median (range), y 51 (20-85)
Race, n (%)
White 46 (75)
African American 5 (8)
Other 4 (7)
Unknown/not reported 6 (10)
Days from diagnosis to study entry, median (range) 4 (0-11)
CBF results (from RT-PCR screening), n (%)
RUNX1-RUNX1T1 20 (33)
CBFB-MYH11 41 (67)
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hypoplastic death, and stopped early if $6 hypoplastic deaths were
observed in the first 20 patients. Efficacy end points included CR rate
with at least 90% power to detect a true rate of $90% (vs the null
hypothesis that this rate was at most 75%). If$50 ($85%) patients
attained a CR, the treatment would be considered promising. These
conservative assumptions were based on the limited knowledge
available at the time of the study design of the possibly toxic effects
of the combination of a KIT inhibitor on the posttreatment recovery
of normal hematopoiesis and thus a potentially high risk of early
hypoplastic death after induction. Furthermore, the enrolled cohort
included older patients with no upper age limit, for whom it was
anticipated that treatment-related toxicity could be relatively high
given the intensity of the proposed cytotoxic regimen.
Efficacy end points included overall survival (OS) and disease-free
survival (DFS). Response and relapse were defined by using
previously published criteria.26 The distributions of OS (time
from study entry to death; patients who were alive were censored
at the time of their last follow-up evaluation) and DFS (time from
documentation of CR to relapse or death; patients who were alive
and relapse-free were censored at the time of their last follow-up
evaluation or at initiation of subsequent therapy, including allogeneic
transplantation) were estimated by using the Kaplan-Meier method.
Log-rank statistics were used to compare survival distributions
between subsets. Simple descriptive statistics were used to
summarize baseline characteristics. Data collection and statistical
analyses were conducted by the Alliance Statistics and Data
Center. Data quality was ensured by review of data by the Alliance
Statistics and Data Center and by the study chairperson following
Alliance policies. Toxicity was graded by using the National Cancer
Institute’s Common Terminology Criteria for Adverse Events version
4.0. The database was locked on 25 October 2016.
Results
Patient demographic characteristics and
molecular features
Between April 2011 and January 2013, we screened 779 patients
newly diagnosed with AML from CALGB/Alliance member institu-
tions for CBF AML by using RT-PCR. The average turnaround time
to report the molecular diagnosis of CBF AML was 48 hours.
Treatment began within a median of 4 days from collection of the
diagnostic sample and shipment to the CALGB/Alliance central
molecular laboratory (interquartile range, 3-5 days). Patients who
had an FLT3 mutation were offered another study.
Sixty-one patients were found positive for RUNX1-RUNX1T1 or
CBFB-MYH11 and were eligible for the CALGB 10801 trial. All
patients (Table 1) were evaluable; of these, 20 and 40 were
subsequently confirmed to harbor t(8;21) or inv(16), respectively,
according to central review of the results of cytogenetic analyses
performed by the CALGB/Alliance–approved institutional labo-
ratories; 1 patient was classified as CBF [inv(16)] based on local
diagnosis. Of the 60 patients whose karyotype was centrally
reviewed, 32 (53%) had additional cytogenetic abnormalities, which
are listed in Table 3. The median age of the treated patients was
51 years (range, 20-85 years); 15 (25%) patients were older
(aged $60 years), 31 (51%) were male, 46 (75%) were white,
41 (67%) were CBFB/MYH11–positive, and 20 (33%) were
RUNX1/RUNX1T1–positive. Eleven (19%) of the 57 patients who
were molecularly evaluable harbored mutated (mut) KIT.
Toxicity
Of the 61 patients, 4 died while receiving this treatment: 3
during induction (2 were older and had CBFB/MYH11 and 1 was
younger with RUNX1/RUNX1T1), and 1 in CR during consolidation
(a younger CBFB/MYH11 patient). Of these 4 deaths, 2 were
within 30 days of start of treatment (1 younger, 1 older). Overall,
10 patients had an adverse event resulting in treatment discontin-
uation (1, 7, and 2 during induction, consolidation, and mainte-
nance, respectively). Ten patients declined to complete the planned
treatment (7 during consolidation, and 3 during maintenance),
but data for the reasons of these voluntary discontinuations were
not consistently reported. “Treatment fatigue” has been reported
in other leukemia trials involving prolonged courses of therapy.27
Among patients who achieved CR and underwent consolidation
treatment, the median number of consolidation cycles received
was 3 (range, 1-4).
The observed hematologic and nonhematologic adverse events
were as expected and similar to those previously reported with this
chemotherapy regimen and/or dasatinib. Pleural effusions (four with
grade 3 and two with grade 4) and abnormal liver function test
results (seven with grade 3 and three with grade 4) possibly
related to dasatinib were observed, although other causes such
as chemotherapy, infection, or antifungal drugs used during the
patient’s treatment may have contributed. Sepsis with respiratory
and/or multiorgan failure was the cause of death in the 4 patients
who died while on protocol treatment.
Fifty-four patients (89%) completed most or all of the planned
consolidation therapy. Thirty-two of all enrolled patients (53%)
started the maintenance therapy, and 19 (53%) of these completed
all 12 monthly cycles. Altogether, 55 (90%), 42 (76%), and 19 (31%)
patients completed induction, consolidation, and maintenance,
respectively. Allogeneic transplantation was performed in 1 patient
during first CR and in 5 others after relapse.
Outcomes
The 30-day survival rate was 97% (59 of 61; 95% confidence
interval [CI], 89-100), with 98% and 93% 30-day survival rates in
the younger and older patients, respectively. Fifty-five patients
(90%; 95% CI, 80-96) achieved CR: 93% of younger patients and
Table 2. Treatment
Drug Dose Route Schedule
Induction
Cytarabine 200 mg/m2/d CIV Days 1-7
Daunorubicin 60 mg/m2/d IV Days 1-3
Dasatinib 100 mg/d Oral Days 8-21
Consolidation
Cycle #1, 2, 3, and 4
HiDAC* 3000 mg/m2 every 12 h IV Days 1,3,5
Dasatinib 100 mg/d Oral Days 6-28
Maintenance
Dasatinib 100 mg/d Oral 12 (28-d) cycles
CIV, continuous IV infusion.
*1000 mg/m2 every 12 hours for patients aged $60 years.
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80% of older patients (Table 4). Six patients failed to achieve CR
because of early death (n 5 3) or refractory disease (n 5 3). Of
these 6 patients, 2 hadRUNX1/RUNX1T1 and 4 hadCBFB/MYH1.
Four patients relapsed during consolidation, five during continuation
and one after protocol treatment was discontinued.
With a median follow-up of 45 months for living patients (range,
1.4-60 months), 10 (16%) patients have relapsed (4 with RUNX1/
RUNX1T1 and 6 with CBFB/MYH11; 6 younger and 4 older).
The 3-year DFS and OS rates were 75% (95% CI, 63-89) and
77% (95% CI, 66-89), respectively, for all patients; 79% (95% CI,
66-94) and 85% (95% CI, 75-97) for younger patients; and
60% (95% CI, 36-100) and 51% (95% CI, 30-85) for older
patients (Table 4; Figure 1).
The 3-year DFS and OS rates are shown in Table 4 and Figure 2.
For patients with RUNX1/RUNX1T1, the 3-year DFS was 71%
(95% CI, 50-100) (80% for younger patients), and the 3-year OS
was 68% (95% CI, 50-93) (78% for younger patients). For those
with CBFB/MYH11, the 3-year DFS was 76% (95% CI, 62-93)
(78% for younger patients), and the 3-year OS was 81% (95% CI,
68-95) (89% for younger patients). Of note, the seemingly longer
DFS than OS in this relatively small study was because 2 patients
went on to non-protocol therapies and were therefore censored for
DFS but continued to be evaluable for OS.
In a post hoc analysis, we assessed the impact of KITmut or high
expression of wild-type (wt) KIT (KITwt) on treatment response. The
3-year DFS and OS rates for patients with KITmut compared with
KITwt were 67% vs 75% (83% vs 77% for younger patients) and
73% vs 76% (88% vs 84% for younger patients), respectively
(Table 5; Figure 3). The 3-year DFS and OS rates for patients with
higher vs lower levels of KITwt expression were 82% vs 72% and
75% vs 80%, respectively.
Discussion
Patients with CBF AML have been classified in a favorable
cytogenetic/genetic risk group, but a relatively large subset of
these patients is not cured despite optimal dosing of induction
and consolidation chemotherapy. Emerging data show that a high
frequency of mutations and/or high expression of KIT in CBF AML
likely result in aberrant tyrosine kinase activity, leukemia cell growth
and survival, and treatment resistance. Thus, we hypothesized that
pharmacologic inhibition of KIT would lead to significant antileuke-
mia activity if combined with an optimized chemotherapy regimen in
patients with CBF AML. Dasatinib is a multi-kinase inhibitor that has
been shown to inactivate KIT at nanomolar concentrations. It has
been previously incorporated into relatively intensive chemotherapy
regimens in Philadelphia chromosome–positive acute lymphoblas-
tic leukemia.28 Furthermore, recent mechanistic findings support
the potential clinical benefit of KIT inhibition in CBF AML.29 Thus,
we elected to conduct a phase 2, open-label, multicenter trial that
evaluated the safety and the clinical activity of dasatinib given in
combination with cytarabine/daunorubicin induction therapy (“713”)
and HiDAC consolidation therapy, and as a single agent for 1 year of
maintenance treatment in patients newly diagnosed with CBF AML.
The rationale for choosing standard-dose cytarabine (200 mg/m2
by continuous infusion over 7 days) and daunorubicin (60 mg/m2
IV for 3 days) as induction chemotherapy was based on the high
CR rates (;90%) observed in previous CALGB/Alliance trials (ie,
CALGB 9621 and CALGB 19808) that used a similar chemother-
apy regimen without a kinase inhibitor.30,31 Furthermore, although
daunorubicin 90 mg/m2 has been shown to be superior to 45 mg/m2
dosing at least in younger patients,32 this higher dose had no
advantage over 60 mg/m2, which had been previously admin-
istered safely and effectively to patients with CBF AML.33,34 For
postremission therapy, repetitive courses of HiDAC have been
shown to be an optimal treatment of patients with CBF AML.35-37
The dose of dasatinib (ie, 100 mg daily) was based on previous
experience combining dasatinib with chemotherapy.28 The admin-
istration of chemotherapy and dasatinib sequentially rather than
concurrently leveraged data supporting potentially synergistic
activity of administration of tyrosine kinase inhibitors following
chemotherapy38; however, whether this is indeed the optimal drug
Table 3. Additional cytogenetic abnormalities in patients with
previously untreated CBF AML
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sequence remains to be fully investigated. A maintenance phase
of dasatinib as a single agent for an additional 12 months after
completion of consolidation chemotherapy was included. Al-
though standard therapy for adults with AML does not routinely
involve maintenance treatment, a small but consistent proportion
of patients with CBF AML have molecular evidence for persistent
minimal residual disease (MRD) following treatment.39 These
patients have an increased risk for later relapse, thereby justifying
the prolonged use of dasatinib maintenance.
The main objectives of this feasibility study were achieved. We
showed that molecular diagnostic evaluation for CBF AML could be
performed in a central molecular pathology laboratory of an National
Cancer Institute–sponsored adult cooperative oncology group
with a short turnaround time between sample submission and
result reporting (median time of 48 hours). The large pool of
patients accessible to a cooperative oncology group allowed
complete accrual for this relatively uncommon subset of CBF
AML to be achieved in only 22 months, despite the low frequency
of this disease (;12% of all AML cases). We showed that the
chemotherapy/dasatinib regimen was tolerable in all patients with
CBF AML, including older individuals. The CR rate was seemingly
equivalent to that reported in previous CALGB/Alliance studies that
used cytarabine/anthracycline/HiDAC–based regimens administered













Younger (n 5 15)
CBFB/MYH11,
Younger (n 5 30)
30 d Survival (95% CI) 97 (89-100) 98 (88-100) 93 (68-100) 95 (75-100) 97.5 (87-100) 93 (68-100) 100 (88-100)
CR 90 93 80 90 90 93 93
36-mo DFS (95% CI) 75 (63-89) 79 (66-94) 60 (36-100) 71 (50-100) 76 (62-93) 80 (58-100) 78 (63-97)
36-mo OS (95% CI) 77 (66-89) 85 (75-97) 51 (30-85) 68 (50-93) 81 (68-95) 78 (59-100) 89 (77-100)
Values are percentages.
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Figure 1. Disease-free and overall survival. DFS (A) and OS (B) for all patients. DFS (C) and OS (D) for patients according to age. Outcomes at 36 months were
calculated by using the Kaplan-Meier (KM) method.
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without a KIT inhibitor.30,31 DFS andOSwere also seemingly comparable
and perhaps superior to those from previous CALGB/Alliance studies.
DFS and OS 3-year rates for CBF patients on CALGB 10801 were
79% and 93% in younger patients compared with 41% and 55% for
similarly aged CBF patients treated on CALGB 9621, and 56% and
67% for those treated on CALGB 19808. However, although these
data provide historical context for the results of CALGB 10801, it
is important to underscore that this study was not designed to
produce a direct comparison of the current vs historical cohorts
of CALGB/Alliance CBF AML patients. Furthermore, although
only a minority of CBF patients harbor FLT3 mutations, and the
prognostic impact of these molecular aberrations in CBF AML remains
uncertain, Alliance CBF AML patients with FLT3 mutations were
offered another study (ie, CALGB 10603).40 Thus, it should be
noted that patients with CBF AML and FLT3 mutations were
likely underrepresented in CALGB 10801 with respect to CALGB
9621 and CALGB 19808 (no FLT3 data are available for these
2 protocols). Nevertheless, the prognostic value of FLT3 mutations
in CBF AML remains to be fully elucidated. Thus, these results need
to be interpreted cautiously, and they require confirmation in larger,
randomized trials.
Older patients enrolled on CALGB 10801 had worse DFS and OS
than younger patients although toxicities did not differ markedly.
Several factors may be responsible, including age-related biological
differences or the lower doses of HiDAC given to older patients































KM Est (95% CI)
36 mo: 76.0 (61.9-93.3%)
36 mo: 70.5 (49.8-99.7%)
+ Censor































KM Est (95% CI)
36 mo: 78.2 (62.9-97.2%)




























KM Est (95% CI)
36 mo: 80.7 (68.7-94.7%)
36 mo: 67.9 (49.6-92.9%)
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36 mo: 78.3 (59.3-100.0%)
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C D
Figure 2. Disease-free and overall survival according to CBF fusion transcripts. DFS (A) and OS (B) for all patients. DFS (C) and OS (D) for younger patients.
Outcomes at 36 months were calculated by using the Kaplan-Meier (KM) method.
Table 5. Clinical results according to KIT status
End point KITmut (n 5 11) KITwt (n 5 46) KITmut, younger (n 5 8) KITwt, younger (n 5 35) KITwt/high (>4.67) (n 5 16) KITwt/low (£4.67) (n 5 24)
CR 91 89 88 94 88 91
36-mo DFS (95% CI) 67 (42-100) 75 (61-92) 83 (58-100) 77 (63-95) 82 (62-100) 72 (54-96)
36-mo OS (95% CI) 73 (51-100) 76 (64-90) 88 (67-100) 84 (72-98) 75 (56-100) 80 (65-100)
Values are percentages.
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(1000 mg/m2 compared with 3000 mg/m2 given to younger patients).
Nevertheless, with DFS and OS rates of 60% and 65% at 2 years,
and 60% and 51% at 3 years, respectively, older patients with CBF
AML seemingly benefited from the CALGB 10801 combined
treatment approach; they had clinical outcomes comparable to
those observed for younger patients on the earlier CALGB 9621
and CALGB 19808 trials.
Although the presence of KITmut has been linked to a worse
outcome in some, but not all, studies (see also Chen et al19), we
noted very similar outcomes for those patients with and those
without an adverse molecular profile enrolled on CALGB 10801,
especially when only the younger patients were considered. Similar
considerations applied for patients presenting with higher KITwt
expression. However, these were post hoc analyses, and the numbers
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Figure 3. Disease-free and overall survival according to KIT status. DFS (A) and OS (B) for all patients (according to KIT mutation status). DFS (C) and OS (D) for
younger patients (according to KIT mutation status). DFS (E) and OS (F) for KITwt patients (according to KIT expression level). Outcomes at 36 months were calculated by
using the Kaplan-Meier (KM) method.
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of subjects with these molecular features were small; therefore, these
results need to be confirmed.
Although the clinical results observed with the dasatinib/chemotherapy
combination are encouraging, we recognize that the CALGB 10801
study had some intrinsic limitations to achieve definitive conclusions
given the current state of the science. These include the single-arm
study design, the relatively small cohort of treated patients, the
uncertain role of dasatinib maintenance postchemotherapy (because
only 19 patients completed this part of the treatment program), the
absence of additional diagnostic studies to define the molecular
landscape of each subject’s disease at diagnosis and relapse, and the
lack of monitoring of molecular aberrations and/or MRD at sequential
time points during and after treatment. These end points will be
explored in future larger Alliance or Intergroup studies of CBF AML.
Of note, during the preparation of the manuscript, a study using
a nearly identical regimen of dasatinib plus chemotherapy in CBF
AML was reported by The Akute Myeloische Leukämie-Studiengruppe
(AMLSG 11-08).41 This study accrued 89 patients with results very
similar to CALGB 10801. The CR/CR with incomplete hematologic
recovery rate was 94%, and the 4-year OS was 74%. However, in an
exploratory analysis, the outcomes ofKITmut patients (n5 19) seemed
somewhat inferior to those of KITwt patients. The AMLSG is currently
conducting a randomized clinical trial comparing a regimen nearly
identical to CALGB 10801 (chemotherapy/dasatinib) vs chemotherapy
alone (#NCT02013648), and that study will provide further insights.
Overall, our findings support further evaluation of KIT inhibitors in
combination with chemotherapy in CBF AML through future larger,
prospective randomized trials. Furthermore, additional pharmaco-
dynamics studies that analyze the impact of dasatinib on aberrantly
activated KIT-dependent pathways are necessary to define and quantify
the pharmacologic activity of this agent on CBF AML blasts. However,
despite our encouraging results, it is evident that even when dasatinib
was added to chemotherapy, not all patients with CBF AML achieved
long-term leukemia-free status. Thus, the treatment approach for patients
with CBF AML should be further refined with the rational addition of
other molecularly targeted agents, such as gemtuzumab ozogamicin,
which has recently been reported in combination with chemotherapy
to confer a clinical benefit to patients with a favorable or intermediate
cytogenetic risk.42-45 Nevertheless, the goal of achieving cure in nearly all
patients with CBF AML seems to be within reach of the next generation
of clinical trials. These should incorporate novel study designs that
include both clinical and molecular end points (ie, MRD) and possibly
early intervention for patients with an impending risk of relapse either
during the treatment or while in the posttreatment follow-up phase.
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2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood. 2017;129(4):424-447.
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